NCT01700959View on ClinicalTrials.gov

Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort

PHASE3CompletedINTERVENTIONAL

Enrollment

911

Participants

Timeline

Start Date

February 6, 2013

Primary Completion Date

April 19, 2017

Study Completion Date

April 19, 2017

Conditions

Cancer Malignancies

Interventions

DRUG

melatonin

Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.

DRUG

placebo

Placebo tablets to match the melatonin will be comprised of inert substances.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

St. Jude Children's Research Hospital

OTHER

NCT01700959 - Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort | Biotech Hunter | Biotech Hunter